Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinosarcoma 2Brain Neoplasms 2Wilms Tumor 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Intraductal Neoplasms 1Ovarian Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Lung Neoplasms 1Locally Advanced Cervical Adenocarcinoma 1Liposarcoma 1Histiocytoma, Malignant Fibrous 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Burkitt Lymphoma 1Barrett Esophagus 1Anus Neoplasms 1Anal Canal Carcinoma 1Adenoma, Islet Cell 1

Interventions

Radiotherapy 3Fluorouracil 3Cisplatin 3Nivolumab 2Mitomycin 2X-Rays 1Watchful Waiting 1Taxes 1Specimen Handling 1Sigmoidoscopy 1Radiation 1Proctoscopy 1Phantoms, Imaging 1Paclitaxel 1Observation 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Immune Checkpoint Inhibitors 1Colonoscopy 1Chemoradiotherapy 1Carboplatin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Anal Canal Carcinoma × X-Rays × Clear all
NCT03233711 2026-05-13

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡